Henry Ford Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (19)

2023

  1. Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study

    BMC Cancer, Vol. 23, Núm. 1

2022

  1. Sex differences in treatment strategy for coronary artery aneurysms: Insights from the international Coronary Artery Aneurysm Registry

    Netherlands Heart Journal, Vol. 30, Núm. 6, pp. 328-334

2019

  1. An international perspective on hospitalized patients with viral community-acquired pneumonia

    European Journal of Internal Medicine, Vol. 60, pp. 54-70

  2. Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention: A Global Expert Consensus Document

    Circulation, Vol. 140, Núm. 5, pp. 420-433

  3. International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia

    Journal of Infection, Vol. 79, Núm. 4, pp. 300-311

  4. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

    Antiviral Research, Vol. 170

2018

  1. Microbiological testing of adults hospitalised with community-acquired pneumonia: An international study

    ERJ Open Research, Vol. 4, Núm. 4

2010

  1. Identifying predictors of central nervous system disease in solid organ transplant recipientswith cryptococcosis

    Transplantation, Vol. 89, Núm. 1, pp. 69-74

  2. Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients

    Clinical Infectious Diseases, Vol. 51, Núm. 9, pp. 1062-1069

2009

  1. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis

    Clinical Infectious Diseases, Vol. 49, Núm. 11, pp. 1721-1728

2008

  1. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: Correlation with outcome in solid organ transplant recipients with cryptococcosis

    Antimicrobial Agents and Chemotherapy, Vol. 52, Núm. 2, pp. 735-738

  2. Central nervous system cryptococcosis in solid organ transplant recipients: Clinical relevance of abnormal neuroimaging findings

    Transplantation, Vol. 86, Núm. 5, pp. 647-651

  3. Pulmonary cryptococcosis in solid organ transplant recipients: Clinical relevance of serum cryptococcal antigen

    Clinical Infectious Diseases, Vol. 46, Núm. 2

2007

  1. Cryptococcus neoformans in organ transplant recipients: Impact of calcineurin-inhibitor agents on mortality

    Journal of Infectious Diseases, Vol. 195, Núm. 5, pp. 756-764

  2. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST clinical status trials

    Journal of the American Medical Association, Vol. 297, Núm. 12, pp. 1332-1343

2006

  1. Late-onset invasive aspergillosis in organ transplant recipients in the current era

    Medical Mycology, Vol. 44, Núm. 5, pp. 445-449

2005

  1. Allograft loss in renal transplant recipients with Cryptococcus neoformans associated immune reconstitution syndrome

    Transplantation, Vol. 80, Núm. 8, pp. 1131-1133

  2. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients

    Clinical Infectious Diseases, Vol. 40, Núm. 12, pp. 1756-1761

  3. Antifungal management practices and evolution of infection in organ transplant recipients with Cryptococcus neoformans infection

    Transplantation, Vol. 80, Núm. 8, pp. 1033-1039